Compare JVA & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | SCNX |
|---|---|---|
| Founded | 1971 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Other Pharmaceuticals |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 24.8M |
| IPO Year | 2005 | 2020 |
| Metric | JVA | SCNX |
|---|---|---|
| Price | $3.82 | $0.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.0K | ★ 1.5M |
| Earning Date | 03-20-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.91 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $89,748,681.00 | $653,391.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.76 | ★ N/A |
| Revenue Growth | 17.92 | ★ 207.88 |
| 52 Week Low | $2.75 | $0.46 |
| 52 Week High | $9.93 | $4.40 |
| Indicator | JVA | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 42.49 |
| Support Level | $3.66 | $0.47 |
| Resistance Level | $3.99 | $0.51 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 48.97 | 21.79 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.